You are here: Industry Insights > Bi

News List

Microbiome Impact on Drug Response and Personalized Medicine Nurah Ekhlaque
February 18, 2025
The gut microbiome impacts drug response and disease management. It affects drug metabolism, efficacy, and toxicity, and is crucial for personalized medicine.
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
February 18, 2025
InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.
The Role of Biosimilars Suzanne Elvidge
February 12, 2025
Biological drugs are therapeutics that are made by living organisms or are created from cells and tissues, and include therapeutic proteins and monoclonal antibodies.
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
Regenerative Medicine and Drug Development: The Intersection of Stem Cells and Biotech Nurah Ekhlaque
January 17, 2025
Explore how regenerative medicine and biotech are transforming drug development with stem cell therapies, personalised treatments, and innovative solutions.
HIV and the Antiretroviral Therapy Capsid Inhibitor Lenacapavir David Orchard-Webb
January 07, 2025
HIV is a major worldwide health issue, producing substantial morbidity and mortality.HIV targets the immune system, primarily CD4+ T cells, depleting them and making the body susceptible to opportunistic infections and malignancies.
China's Innovative Drugs Hunt for Billion Dollar Molecule Xiaobin
December 20, 2024
The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.
Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
How to Source Safe and Effective Antibiotic APIs for Pediatric Formulations Saher Haider
December 09, 2024
Given children's unique physiological and pharmacokinetic characteristics, the development of pediatric antibiotic formulations requires stringent controls.
Has the Booming PD-1 Inhibitor Reached its Limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.